“Clinical and neurobiological findings suggest that the cannabinoids and the endocannabinoid system may be implicated in the pathophysiology and treatment of schizophrenia.
Our results reinforce the role of the endocannabinoid system in the sensorimotor gating impairment related to schizophrenia, and point to cannabinoid drugs as potential therapeutic strategies.”
“Cannabis sativa has been cultivated throughout human history as a source of fiber, oil and food, and for its medicinal and intoxicating properties.
The availability of the Cannabis sativa genome enables the study of a multifunctional plant that occupies a unique role in human culture. Its availability will aid the development of therapeutic marijuana strains with tailored cannabinoid profiles and provide a basis for the breeding of hemp with improved agronomic characteristics.”
“The use of cannabis as a therapeutic agent for various medical conditions has been well documented…The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of Parkinson disease (PD).
Analysis of specific motor symptoms revealed significant improvement after treatment…
There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed.
The study suggests that cannabis might have a place in the therapeutic armamentarium of PD.”
“…the Cannabis sativa herb has been known for its therapeutic benefit for centuries… interest in the clinical potential of cannabinoid-based drugs escalated after the discovery of the endocannabinoid system… therapeutic applications of cannabinoids (plant-derived or synthetic)… may constitute a useful addition to the pharmacotherapeutic armamentarium in chronic conditions insufficiently alleviated by existing drugs.” http://www.ncbi.nlm.nih.gov/pubmed/22646020
“The endocannabinoid system and its therapeutic exploitation.” http://www.ncbi.nlm.nih.gov/pubmed/15340387
“Cannabinoid receptors as therapeutic targets.” http://www.ncbi.nlm.nih.gov/pubmed/16402900
“Cannabinoids.” http://www.ncbi.nlm.nih.gov/pubmed/16266285
“Plant, synthetic, and endogenous cannabinoids in medicine.” http://www.ncbi.nlm.nih.gov/pubmed/16409166
“The effectiveness of cannabidiolic acid (CBDA) was compared with other potential treatments for anticipatory nausea (AN), using a rat model of contextually elicited conditioned gaping reactions…
CBDA has therapeutic potential as a highly potent and selective treatment for AN without psychoactive or locomotor effects.”
“Phototherapy is a powerful, noninvasive approach for cancer treatment, with several agents currently in clinical use.
…we developed a phototherapy agent that combines a functional ligand and a near infrared phthalocyanine dye. Our target is type 2 cannabinoid receptor (CB2R), considered an attractive therapeutic target for phototherapy given it is overexpressed by many types of cancers that are located at a surface or can be reached by an endoscope.
Overall, this opens up the opportunity for development of an alternative treatment option for CB2R-positive cancers.”
“More than 60% of advanced cancer patients suffer from anorexia and cachexia.
This review focuses on the possible mechanisms by which the endocannabinoid system antagonizes cachexia-anorexia processes in cancer patients and how it can be tapped for therapeutic applications.
Cannabinoids stimulate appetite and food intake…
Cannabinoid type 1 receptor activation stimulates appetite and promotes lipogenesis and energy storage.
Further study of cancer-cachexia pathophysiology and the role of endocannabinoids will help us to develop cannabinoids without psychotropic properties, which will help cancer patients suffering from cachexia and improve outcomes of clinical antitumor therapy.”
“The endocannabinoid system, comprising lipid-derived endocannabinoids, their G-protein-coupled receptors (GPCRs), and the enzymes for their metabolism, is emerging as a promising therapeutic target in cancer.
This report highlights the main signaling pathways for the antitumor effects of the endocannabinoid system in cancer and its basic role in cancerpathogenesis, and discusses the alternative view of cannabinoid receptors as tumor promoters.
We focus on new players in the antitumor action of the endocannabinoid system and on emerging crosstalk among cannabinoid receptors and other membrane or nuclear receptors involved in cancer.”
“According to a new study published in the journal PloS ONE, researchers from Mount Sinai School of Medicine discovered that marijuana-like compounds can inhibit the multiplication of human immunodeficiency virus (HIV) in late-stage AIDS by acting on viral receptors…
“We knew that cannabinoid drugs like marijuana can have a therapeutic effect in AIDS patients, but did not understand how they influence the spread of the virus itself. We wanted to explore cannabinoid receptors as a target for pharmaceutical interventions that treat the symptoms of late-stage AIDS and prevent further progression of the disease…”
“Patients suffering from Alzheimer’s disease (AD) exhibit a decline in cognitive abilities including an inability to recognise familiar faces…
The non-psychoactive phytocannabinoid cannabidiol (CBD) exerts neuroprotective, anti-oxidant and anti-inflammatory effects and promotes neurogenesis. CBD also reverses Aβ-induced spatial memory deficits in rodents.
This is the first study to investigate the effect of chronic CBD treatment on cognition in an AD transgenic mouse model.
Our findings suggest that CBD may have therapeutic potential for specific cognitive impairments associated with AD.”